Genetic studies have shown that mutations of complement inhibitors such as membrane
cofactor protein, Factors H, I, or B and C3 predispose patients to atypical hemolytic uremic …

Factor I (FI) is the major complement inhibitor that degrades C3b and C4b in the presence of
cofactors such as factor H (FH) and membrane cofactor protein (MCP). Recently, mutations …

Mutations in the plasma complement regulator factor H (CFH) and the transmembrane
complement regulator membrane co-factor protein (MCP) have been shown to predispose to …

Mutations in factor H (CFH), factor I (IF), and membrane cofactor protein (MCP) genes have
been described as risk factors for atypical hemolytic uremic syndrome (aHUS). This study …

The past decade has seen the identification of mutations in the genes for complement factor
H (CFH)(1–6), membrane co-factor protein (MCP)(7–12), and factor I (CFI)(9, 13–15) as …

The complement system is regulated by inhibitors such as factor I (FI), a serine protease that
degrades activated complement factors C4b and C3b in the presence of specific cofactors …

Background and objectives: Atypical hemolytic uremic syndrome (aHUS) is associated with
mutations in genes encoding complement-regulatory proteins factor H, I and B and …

Recent studies have identified mutations in the complement regulatory gene factor I (CFI)
that predispose to atypical hemolytic uremic syndrome (aHUS). CFI is a two-chain serine …

Background: Genetic defects in complement proteins reportedly contribute to the atypical
hemolytic uremic syndrome (aHUS). Numerous genetic studies have been published in …

Mutations in the gene encoding complement factor H (CFH) that alter the C3b/polyanions-
binding site in the C-terminal region impair the capacity of factor H to protect host cells …